Phase II/III trials of umibecestat to discontinue for Alzheimer’s disease: industry news round-up

Written by Sharon Salt, Editor

In this week’s industry news round-up we cover the latest headlines on trial discontinuations in both the Alzheimer’s and ALS fields, alongside a drug discovery shift from the amyloid approach in Alzheimer’s disease. Find out more about our selection of the headlines below: ADDF clinical trial report demonstrates notable shift from amyloid approach Phase II/III trials of umibecestat to be discontinued for Alzheimer’s disease ALS clinical trial investigating the use of Acthar® Gel halted over concerns for pneumonia ADDF clinical trial report demonstrates notable shift from amyloid approach A new clinical trial report, which has been released by the Alzheimer’s...

To view the full article, please register now for access

It's completely free